Format

Send to

Choose Destination
J Hum Genet. 2017 Jan;62(1):49-56. doi: 10.1038/jhg.2016.84. Epub 2016 Jun 30.

Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma.

Author information

1
Department of Functional Genomics, Graduate School of Medicine, Chiba University, Chiba, Japan.
2
Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Abstract

Bladder cancer (BC) and renal cell carcinoma (RCC) are frequently diagnosed urinary tract cancers. Recently developed molecular-targeted therapies for RCC have shown remarkable therapeutic efficacy; however, no targeted therapeutics are currently approved for the treatment of BC, and few effective treatment options exist. Current studies have shown that small noncoding RNA molecules have major roles in cancer cells. MicroRNAs (miRNAs) are endogenous small noncoding RNA molecules that regulate protein-/nonprotein-coding RNAs in human cells. A large body of evidence suggests that aberrantly expressed miRNAs are deeply involved in the pathogenesis of human cancers. In this paper, we review recently published miRNA expression signatures of BC and RCC. We focus on downregulated or upregulated miRNAs in multiple signatures and discuss putative target genes of miRNAs. Comparisons of RCC and BC expression signatures revealed that the two types of cancer showed opposite expression patterns for miR-200 family miRNAs (i.e., miR-141/200c and miR-200a/200b/429). We discuss in silico analysis of genes targeted by miR-200 family miRNAs and the molecular mechanisms underlying BC and RCC.

PMID:
27357429
DOI:
10.1038/jhg.2016.84
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center